A Phase II Study of Anlotinib in STS Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

166

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

October 31, 2015

Study Completion Date

April 30, 2017

Conditions
Cancer
Interventions
DRUG

Anlotinib

Trial Locations (16)

100021

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing

100039

Chinese PLA General Hospital, Beijing

Unknown

The 1st affiliated hospital of bengbu medical college, Bengbu

Beijing Cancer Hospital, Beijing

Beijing Jishuitan Hospital, Beijing

Peking Union Medical College Hospital, Beijing

Fujian Province Cancer Hospital, Fuzhou

The First Affiliated Hospital of Fujian Meidical University, Fuzhou

Gansu Province Tumor Hospital, Lanzhou

Sun Yat-Sen University Cancer Center, Guangzhou

Guangxi medical university affiliated tumor hospital, Nanning

Harbin medical university affiliated tumor hospital, Harbin

Liaoning Province Tumor Hospital, Shenyang

Cancer Hospital of Fudan University, Shanghai

Shanghai 6th People's Hospital, Shanghai

Tianjin Medical University Cancer Hospital, Tianjin

All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY